- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.01. | MapLight Therapeutics: Aktie steigt nach beschleunigtem Zeitplan für klinische Studien | 1 | Investing.com Deutsch | ||
| 09.01. | MapLight Therapeutics zieht Zeitplan für Phase-2-Studienergebnisse vor | 2 | Investing.com Deutsch | ||
| 09.01. | MapLight Therapeutics accelerates timeline for Phase 2 trial results | 2 | Investing.com | ||
| MAPLIGHT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.01. | MapLight Therapeutics, Inc.: MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 | 696 | GlobeNewswire (Europe) | SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing... ► Artikel lesen | |
| 09.01. | MapLight Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.01. | MapLight Dims on FDA Nod | 1 | Baystreet.ca | ||
| 05.01. | FDA grants fast track designation to MapLight's Alzheimer's drug | 2 | Investing.com | ||
| 05.01. | MapLight Therapeutics' Alzheimer's Psychosis Drug Granted FDA Fast Track Status | 1 | RTTNews | ||
| 05.01. | MapLight Therapeutics, Inc.: MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis | 329 | GlobeNewswire (Europe) | SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. ("MapLight") (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast... ► Artikel lesen | |
| 16.12.25 | SandboxAQ und MapLight schließen 200-Millionen-Dollar-Allianz zur Erforschung von ZNS-Wirkstoffen | 1 | Investing.com Deutsch | ||
| 16.12.25 | SandboxAQ and MapLight form $200 million CNS drug discovery alliance | 2 | Investing.com | ||
| 16.12.25 | MapLight Therapeutics, Inc.: SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies | 128 | GlobeNewswire (Europe) | SAN FRANCISCO and BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- SandboxAQ and MapLight Therapeutics, Inc. (Nasdaq: MPLT) announced today that the companies have entered into a strategic collaboration... ► Artikel lesen | |
| 09.12.25 | MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes | 1 | Seeking Alpha | ||
| 04.12.25 | MapLight Therapeutics, Inc.: MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress | 146 | GlobeNewswire (Europe) | Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer's disease psychosis... ► Artikel lesen | |
| 04.12.25 | MapLight Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.12.25 | MapLight Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12.25 | MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug | 2 | Investing.com | ||
| 03.12.25 | Jefferies bekräftigt "Buy"-Rating: MapLight-Aktie legt dank Schizophrenie-Wirkstoff zu | 1 | Investing.com Deutsch | ||
| 21.11.25 | Leerink Partners startet Coverage für MapLight Therapeutics mit "Outperform" | 3 | Investing.com Deutsch | ||
| 21.11.25 | MapLight Therapeutics stock initiated with Outperform rating by Leerink Partners | 1 | Investing.com |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 309,11 | 0,00 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| COGENT BIOSCIENCES | 37,960 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,74 | +0,23 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,650 | -0,27 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,060 | -2,77 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ARCELLX | 69,47 | 0,00 % | Arcellx präsentiert Daten zu Anito-Cel auf den Tandem Meetings 2026 | ||
| ARCUTIS BIOTHERAPEUTICS | 25,570 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis | 58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 75,62 | +4,03 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 65,93 | +2,15 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| ERASCA | 10,610 | 0,00 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| RECURSION PHARMACEUTICALS | 4,175 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| LENZ THERAPEUTICS | 16,300 | +3,03 % | New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug | ||
| ALUMIS | 26,420 | +7,79 % | ALUMIS INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| VERA THERAPEUTICS | 45,300 | 0,00 % | Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer | BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments... ► Artikel lesen |
Das Unternehmen MAPLIGHT THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,36 % bei einem Aktienkurs von 17,930 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAPLIGHT THERAPEUTICS INC finden Sie auf Wallstreet Online.